Mitochondrial protein ATPase family, AAA domain containing 3A correlates with radioresistance in glioblastoma

Neuro-Oncology

Volumn 15, Issue 10, 2013, Pages 1342-1352

  You, Weir Chiang ^a,b   Chiou, Shiow Her ^b   Huang, Chih Yang ^b   Chiang, Shu Fen ^b,c   Yang, Cheng Lin ^b   Sudhakar, Janaki N ^b   Lin, Tze Yi ^c   Chiang, I Ping ^c   Shen, Chiung Chyi ^a,d   Cheng, Wen Yu ^a,b,e   Lin, Jin Chin ^a   Shieh, Shwn Huey ^f   Chow, Kuan Chih ^b  

^a TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^c CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d NATIONAL YANG MING UNIVERSITY   (Taiwan)

^e HUNGKUANG UNIVERSITY   (Taiwan)

^f CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

ATAD3A; autophagy; DNA repair; glioblastoma multiforme; radiation

Indexed keywords

6 O METHYLGUANINE; AAA DOMAIN CONTAINING 3A PROTEIN; ADENOSINE TRIPHOSPHATASE; DNA METHYLTRANSFERASE; HISTONE H2AX; HISTONE H3; O 6 DNA METHYLGUANINE METHYLTRANSFERASE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CELL DEATH; CELL SURVIVAL; CELL VIABILITY; CHEMORADIOTHERAPY; CONTROLLED STUDY; DNA DAMAGE; DNA METHYLATION; DNA REPAIR; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MALE; PROTEIN EXPRESSION; RADIOSENSITIVITY; TREATMENT RESPONSE; TUMOR CELL LINE;

ATAD3A; AUTOPHAGY; DNA REPAIR; GLIOBLASTOMA MULTIFORME; RADIATION;

ADENOSINE TRIPHOSPHATASES; ANTINEOPLASTIC AGENTS, ALKYLATING; BLOTTING, WESTERN; BRAIN NEOPLASMS; CELL DIFFERENTIATION; CELL PROLIFERATION; CHEMORADIOTHERAPY; DACARBAZINE; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MITOCHONDRIA; MITOCHONDRIAL PROTEINS; NEOPLASM STAGING; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; PROGNOSIS; RADIATION TOLERANCE; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; SURVIVAL RATE; TUMOR CELLS, CULTURED;

EID: 84885011443     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/not077     Document Type: Article

References (43)

1. Stupp R, Hegi ME, MasonWP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10:459-466.
2. Andreana LR, Christopher EP,Mark R, et al.MGMTpromotermethylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma. Neuro Oncol 2010 12 116-121.
3. Nobusawa S,Watanabe T, Kleihues P, Ohgaki H. IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res. 2009;15:6002-6007.
4. Labussière M, Idbaih A, Wang XW, et al. All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2. Neurology. 2010;74(23): 1886-1890.
5. Kaneshiro D, Kobayashi T, Chao ST, Suh J, Prayson RA. Chromosome 1p and 19q deletions in glioblastoma multiforme. Appl Immunohistochem Mol Morphol. 2009;17(6):512-516.
6. Squatrito M, BrennanCW, Helmy K, Huse JT, Petrini JH, Holland EC. Loss of ATM/Chk2/p53 pathway components accelerates tumor development and contributes to radiation resistance in gliomas. Cancer Cell. 2010;18(6):619-629.
7. Roy K,Wang L, MakrigiorgosGM,Price BD. Methylation of theATMpromoter in glioma cells alters ionizing radiation sensitivity. BiochemBiophys Res Commun. 2006;344(3):821-826.
8. Tribius S, Pidel A, Casper D. ATMprotein expression correlates with radioresistance in primary glioblastoma cells in culture. Int J Radiat Oncol Biol Phys. 2001;50(2):511-523. (Pubitemid 32472281)
9. Choi S,GamperAM,White JS, Bakkenist CJ. Inhibition ofATMkinase activity does not phenocopy ATMprotein disruption: implications for the clinical utility of ATM kinase inhibitors. Cell Cycle. 2010;9(20):4052-4057.
10. Valentin-Vega YA, Maclean KH, Tait-Mulder J, et al. Mitochondrial dysfunction in ataxia-telangiectasia. Blood. 2012;119(6):1490-1500.
11. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324:1029-1033.
12. Modica-Napolitano JS, Kulawiec M, Singh KK. Mitochondria and human cancer. Curr Mol Med. 2007;7:121-131. (Pubitemid 46322283)
13. Dmitrenko V, Shostak K, Boyko O, et al. Reduction of the transcription level of the mitochondrial genome in human glioblastoma. Cancer Lett. 2005;218:99-107. (Pubitemid 40082706)
14. Kirches E, Krause G,Warich-KirchesM,et al. High frequency ofmitochondrial DNA mutations in glioblastoma multiforme identified by direct sequence. Int J Cancer. 2001;93(4):534-538. (Pubitemid 32701412)
15. de Moura MB, dos Santos LS, Van HB. Mitochondrial dysfunction in neurodegenerative diseases. Environ Mol Mutagen. 2010;51(5):391-405.
16. Griguer CE, Oliva CR. Bioenergetics pathways and therapeutic resistance in gliomas: emerging role of mitochondria. Curr Pharm Des. 2011;17(23):2421- 2427.
17. Gilquin B, Cannon BR, Hubstenberger A, et al. The calcium-dependent interaction between S100B and the mitochondrial AAA ATPase ATAD3A and the role of this complex in the cytoplasmic processing of ATAD3A. Mol Cell Biol. 2010;30:2724-2736.
18. Chiang SF, Huang CY, Lin TY, Chiou SH, Chow KC. An alternative import pathway of AIF to the mitochondria. Int J Mol Med. 2012;29:365-372.
19. FangHY, Chang CL, Hsu SH, et al. ATPase family AAAdomain-containing 3A is a novel anti-apoptotic factor in lung adenocarcinoma cells. J Cell Sci. 2010;123:1171-1180.
20. Geuijen CA, Bijl N, Smit RC, et al. A proteomic approach to tumour target identification using phage display, affinity purification and mass. Eur J Cancer 2005;41:178-187. (Pubitemid 40029671)
21. Gires O, Munz M, Schaffrik M, et al. Profile identification of disease-associated humoral antigens using AMIDA, a novel proteomicsbased technology. Cell Mol Life Sci. 2004;61:1198-1207. (Pubitemid 38703749)
22. ChenTC,HungYC,LinTY, et al.Humanpapillomavirus infectionandexpression of ATPase family AAA domain containing 3A, a novel anti-autophagy factor, in uterine cervical cancer. Int JMolMed. 2011 28 689-696.
23. Huang KH, Chow KC, Chang HW, Lin TY, Lee MC. ATPase family AAA domain containing 3Ais an anti-apoptotic factor and a secretion regulator of PSA in prostate cancer. Int J Mol Med. 2011;28:9-15.
24. Hubstenberger A, Labourdette G, Baudier J, Rousseau D. ATAD 3A and ATAD 3B are distal 1p-located genes differentially expressed in human glioma cell lines and present in vitro anti-oncogenic and chemoresistant properties. Exp Cell Res. 2008;314:2870-2883.
25. Smith JS, Alderete B, Minn Y, et al. Localization of common deletion regions on 1p and 19q in human glioma and their association with histological subtype. Oncogene. 1999;18(28):4144-4152. (Pubitemid 29363922)
26. Stupp R, Hegi ME, van den Bent MJ, et al. Changing paradigms-an update on the multidisciplinary management of malignant glioma. Oncologist. 2006;11(2):165-180. (Pubitemid 43261763)
27. RemmeleW, Schicketanz KH. Immunohistochemical determination of estrogen and progesterone receptor content in human breast cancer. Computer-assisted image analysis (QIC score) vs. subjective grading (IRS). Pathol Res Pract. 1993;189:862-866. (Pubitemid 23308006)
28. Challberg MD, Kelly TJ, Jr. AdenovirusDNA replication in vitro: origin and direction of daughter strand synthesis. J Mol Biol. 1979;135(4): 999-1012. (Pubitemid 10187141)
29. Ambrose M, Goldstine JV, Gatti RA. Intrinsic mitochondrial dysfunction in ATM-deficient lymphoblastoid cells. Hum Mol Genet. 2007;16(18): 2154-2164. (Pubitemid 47354898)
30. Tentori L, Portarena I, Torino F, Scerrati M, Navarra P, Graziani G. Poly(ADP-ribose) polymerase inhibitor increases growth inhibition and reduces G(2)/Mcell accumulation induced bytemozolomide in malignant glioma cells. Glia. 2002;40:44-54. (Pubitemid 35181342)
31. Oliva CR, Nozell SE, Diers A, et al. Acquisition of temozolomide chemoresistance in gliomas leads to remodeling ofmitochondrial electron transport chain. J Biol Chem. 2010;285:39759-39767.
32. Le CalvéB, Rynkowski M, Le Mercier M, et al. Long-term in vitro treatment of human glioblastoma cells with temozolomide increases resistance in vivo through up-regulation of GLUT transporter and aldoketo reductase enzyme AKR1C expression. Neoplasia. 2010;12: 727-739.
33. Chen J, Emara N, Solomides C, Parekh H, Simpkins H. Resistance to platinum-based chemotherapy in lung cancer cell lines. Cancer Chemother Pharmacol. 2010;66(6):1103-1111.
34. Deng HB, Parekh HK,ChowKC, Simpkins H. Increased expression of dihydrodiol dehydrogenase induces resistance to cisplatin in human ovarian carcinoma cells. J Biol Chem. 2002;277:15035-15043. (Pubitemid 34952580)
35. Hung JJ, Chow KC,WangHW,Wang LS. Expression of dihydrodiol dehydrogenase and resistance to chemotherapyand radiotherapy in adenocarcinoma cells of lung. Anticancer Res. 2006;26:2949-2955.
36. Eaton JS, Lin ZP, Sartorelli AC, Bonawitz ND, Shadel GS. Ataxia-telangiectasia mutated kinase regulates ribonucleotide reductase and mitochondrial homeostasis. J Clin Invest. 2007;117(9):2723-2734. (Pubitemid 47494372)
37. Watters D,KedarP, Spring K, et al. Localization of a portion of extranuclear ATMto peroxisomes. J Biol Chem. 1999;274(48):34277-34282. (Pubitemid 129511769)
38. Li J, Han YR, Plummer MR, Herrup K. Cytoplasmic ATMin neurons modulates synaptic function. Curr Biol. 2009;19(24):2091-2096.
39. Cascone A, Bruelle C, Lindholm D, Bernardi P, Eriksson O. Destabilization of the outer and inner mitochondrial membranes by core and linker histones. PLoS One. 2012;7(4):e35357.
40. Rone MB, Midzak AS, Issop L, et al. Identification of a dynamic mitochondrial protein complex driving cholesterol import, trafficking, and metabolism to steroid hormones. Mol Endocrinol. 2012;26(11):1868-1882.
41. Meador JA, Zhao M, Su Y, Narayan G, Geard CR, Balajee AS. Histone H2AX is a critical factor for cellular protection against DNA alkylating agents. Oncogene. 2008;27(43):5662-5671.
42. Rabinowitz JD, White E. Autophagy and metabolism. Science. 2010;330:1344-1348.
43. Ha HC, Snyder SH. Poly(ADP-ribose) polymerase is a mediator of necrotic cell death by ATP depletion. Proc Natl Acad Sci U S A. 1999;96(24):13978-13982.